[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643831":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":25,"locations":30,"responsibleParty":44,"collaborators":25,"id":48,"slug":25,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":25,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":25,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":25,"overallStatus":67,"whyStopped":25,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Shanghai Jiao Tong University Affiliated Sixth People's Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"liposomal bupivacaine","EXPERIMENTAL","5 ml of plain bupivacaine 0.75% will be mixed with 10 ml liposomal bupivacaine (133mg)",[13],"Drug: liposomal bupivacaine",{"label":15,"type":16,"description":17,"interventionNames":18},"normal saline","PLACEBO_COMPARATOR","5 ml of plain bupivacaine 0.75% will be combined with 10 ml of normal saline",[19],"Drug: Normal Saline",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Prepare a local anesthetic by combining liposomal bupivacaine (133 mg\u002F10 mL) and bupivacaine hydrochloride (75 mg\u002F10 mL) in a 2:1 volume ratio.",[9],null,{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Normal Saline","Prepare a local anesthetic by combining normal saline (10 mL) and bupivacaine hydrochloride (75 mg\u002F10 mL) in a 2:1 volume ratio.",[15],[31],{"facility":32,"status":25,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":25},"Shanghai sixth people's hospital","Shanghai","Shanghai Municipality","200233","China","CN",{"type":39,"coordinates":40},"Point",[41,42],121.45806,31.22222,{"lat":42,"lon":41},{"type":45,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Tao Xu","Ph.D.","100643831",false,"NCT07606911","Effect of Liposomal Bupivacaine on Rebound Pain After Peripheral Nerve Block in Orthopedic Surgery.","Liposomal Bupivacaine Combined With Plain Bupivacaine for Peripheral Nerve Block to Reduce Rebound Pain After Orthopedic Extremity Surgery: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* 18-65 years old;\n* ASA Physical Status 1-3;\n* Scheduled for elective unilateral orthopedic surgery of the upper or lower extremity.\n\nExclusion Criteria:\n\n* Women who are pregnant or breastfeeding;\n* Bupivacaine sensitivity or known allergy;\n* Contraindication for nerve blocks;\n* Enrollment in another clinical trial that could confound pain evaluation;\n* Other conditions that preclude study participation.","ALL","18 Years","65 Years",{"count":58,"type":59},668,"ESTIMATED","INTERVENTIONAL",[62],"PHASE4","This study will prospectively compare the preventive effect of liposomal bupivacaine combined with plain bupivacaine versus plain bupivacaine alone on rebound pain after nerve block in patients undergoing orthopedic extremity surgery. The primary aim is to assess whether the combination reduces the incidence or severity of rebound pain (i.e., more effectively covers the postoperative inflammatory peak on days 2-3 and provides a smoother regression curve of sensory blockade). Secondary aims include evaluation of upper limb functional scores, occurrence of chronic pain, and health-related quality of life. All aims will be assessed over 72 hours or the duration of hospitalization if shorter.",[65,66],"Acute Pain","Orthopaedic Surgery","NOT_YET_RECRUITING","2026-06-07",{"date":70,"type":71},"2026-06-09","ACTUAL",{"date":73,"type":59},"2026-07-01",{"date":75,"type":59},"2027-12-01",{"name":5,"class":6},1]